Stop Drug related deaths increasing
Doctors
To change failed policies now
pediatricians, obstetricians, surgeons, addiction specialists and more
Latest Newsletter
Progress in Hepatitis C treatment
Campaign
ACT NOW
Latest Newsletter
HCV treatment
Campaign
Shadow
More >
In The News
The Futile Cruelty of the US-Led Drug War in Afghanistan⁠—What Now?
The Futile Cruelty of the US-Led Drug War in Afghanistan⁠—What Now?
A report published last month by the Washington Post confirmed what many already knew about the war on opium in Afghanistan: A staggering, costly failure.
Opioid Deaths Rise When Auto Plants Close, Study Shows
Opioid Deaths Rise When Auto Plants Close, Study Shows
Research found 85 percent more deaths among those of prime working age in places where car factories closed compared with where they stayed open.
Walk-in clinics for opioid addiction offer meds first, fast
Walk-in clinics for opioid addiction offer meds first, fast
The epidemic is driving new treatment strategies for the 2 million Americans addicted to opioids.
More >
Publications
Drug Decriminalization: A Matter of Justice and Equity, Not Just Health Since 2016, more than 10,300 Canadians have died of an apparent opioid-related overdose, with the majority involving fentanyl or fentanyl analogs
EMCDDA operating guidelines for the European Union Early Warning System on new psychoactive substances These guidelines provide the rationale, steps, procedures, roles, and responsibilities for the operation of the EU Early Warning System. They reflect the requirements of Regulation (EC) No 1920/2006 (as amended) and Council Framework Decision 2004/757/JHA (as amended) with respect to information exchange and the early warning system, as well as for the initial report, risk assessment, and control measures.
Series from the Lancet journals on Drug Use The drug use landscape is dynamic and changing. Changes in public attitudes and laws towards drug use have occurred in an increasing number of countries. Global drug production and consumption are increasing as are the risks and harms to health, while new substances continue to emerge. This Series focuses on opioids, cannabinoids, stimulants, and new psychoactive substances. The Series authors review the evidence on the epidemiology of drug use and related harms and interventions (treatment and policies) to address them. They highlight issues that are likely to become increasingly important in the next decade.